Autoinjectors Market Report 2025

This Autoinjectors market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The autoinjectors market size has grown exponentially in recent years. It will grow from $3.7 billion in 2024 to $4.55 billion in 2025 at a compound annual growth rate (CAGR) of 22.8%. The growth in the historic period can be attributed to increased prevalence of chronic diseases, growth in aging population, rise in biotechnology and pharmaceutical sector, rise in patient preference for self-administration, regulatory support.

The autoinjectors market size is expected to see exponential growth in the next few years. It will grow to $10.07 billion in 2029 at a compound annual growth rate (CAGR) of 22%. The growth in the forecast period can be attributed to expansion ofTherapeutic applications, rising healthcare costs, increased focus on patient-centered care, telemedicine and remote patient monitoring, emerging markets. Major trends in the forecast period include personalized drug delivery, connected and smart autoinjectors, needle-free autoinjectors, biologic drug delivery, safety and security features.

The rising prevalence of chronic diseases is expected to drive growth in the autoinjectors market in the upcoming years. Chronic diseases are defined as illnesses that last for a year or longer and require ongoing medical attention. Conditions such as heart disease, cancer, rheumatoid arthritis, and diabetes are among the leading causes of mortality and disability worldwide. Autoinjector devices are designed for multiple injections of biologics and hormones in patients who need regular doses for the long-term management of conditions like diabetes and rheumatoid arthritis. For example, in January 2022, research published by the American Cancer Society, a US-based health organization, projected that there would be 609,360 cancer deaths and 1.9 million new cancer cases in the US for that year, which translates to approximately 1,670 fatalities each day. This rising prevalence of chronic diseases is propelling the growth of the autoinjectors market, as these devices offer a convenient and effective solution for patients requiring regular medication.

Rising healthcare expenditure is anticipated to boost the autoinjectors market. Healthcare expenditure refers to the total amount of money spent on healthcare services, goods, and activities within a specific healthcare system or economy over a defined period. Increased healthcare expenditure supports the development, affordability, and accessibility of autoinjectors for patients. Moreover, greater demand for autoinjectors can drive innovation in the field of autoinjector development. As an illustration, according to a report published by the UK's Office for National Statistics in May 2023, healthcare spending in the UK increased by 9.4% in nominal terms and 9.7% in real terms between 2020 and 2021. In 2021, total healthcare expenditure in the UK reached $367.25 billion (£280.7 billion), with pharmaceutical expenditure at $51.84 billion (£39.6 billion), and spending on preventive care more than doubling from 2020, totaling $45.93 billion (£35.1 billion). Thus, rising healthcare expenditures are playing a significant role in propelling the autoinjectors market.

The rise of technological advancements is significantly influencing the autoinjectors market. Key players in the autoinjectors sector are concentrating on developing innovative solutions to fulfill the demand for a delivery mechanism for viscous biologics. For example, in May 2023, Boehringer Ingelheim, a Germany-based pharmaceutical company, announced that its Cyltezo Pen, an autoinjector option for Cyltezo (adalimumab-adbm), received approval from the U.S. Food and Drug Administration (FDA). Cyltezo is authorized for the treatment of various chronic inflammatory diseases. The 40 mg/0.8 mL pre-filled Cyltezo Pen will be available in packs of two, four, and six.

Major companies in the auto-injectors market are focused on developing innovative products to address the growing demand for sustainable drug delivery devices while offering more cost-effective solutions for self-administered drug delivery. One such innovative product is the Qfinity auto-injector platform, designed to be both sustainable and affordable. The platform incorporates durable materials capable of withstanding over 100 injections and features a pre-filled disposable cassette system that minimizes waste. For example, in May 2022, Jabil Inc., a US-based healthcare manufacturing company, introduced the Qfinity auto-injector platform. This platform is a straightforward, reusable, and modular solution for self-administering subcutaneous (SC) drugs, including larger-volume and higher-viscosity medicines. It offers sustainability, cost-effectiveness, versatility, ease of use, accuracy, safety, portability, and durability for self-administered drug delivery.

In April 2022, Halozyme Therapeutics Inc., a US-based biotechnology company, acquired Antares Pharma Inc. for $960 million. This strategic acquisition is aimed at expanding Halozyme Therapeutics Inc.'s portfolio of drug delivery technologies and gaining access to Antares' commercial infrastructure. The acquisition positions them to become a leading company in the field of drug delivery. Antares Pharma Inc. is a US-based pharmaceutical product development company specializing in the development of auto-injectors. This acquisition will likely enhance Halozyme's capabilities in delivering innovative drug delivery solutions, including auto-injectors, to a broader market.

Major companies operating in the autoinjectors market include AbbVie Inc., Mylan N.V., Eli Lilly and Company, Amgen Inc., Becton, Dickinson and Company, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Pfizer Inc., Bayer AG, Biogen Inc., AstraZeneca PLC, Haselmeier GmbH, Owen Mumford Ltd., Gerresheimer AG, Philip Morris International Inc., Oval Medical Technologies Ltd., Solteam Incorporation Co. Ltd., Elcam Medical Group (E3D) Ltd., Jabil Inc., Catalent Inc., SHL Medical AG, West Pharmaceutical Services Inc., Nemera Development S.A., Bespak Europe Ltd., AptarGroup Inc., Consort Medical plc, Terumo Corporation, Nipro Corporation, Medtronic plc, Integra LifeSciences Corporation, OssDsign AB, Xenco Medical LLC, Renishaw plc.

An autoinjector is a device designed for self-administering a single, predetermined dose of medication into the body. Typically, it features a spring-loaded syringe that is activated upon firm pressure against the body.

The primary types of autoinjectors are disposable autoinjectors and reusable autoinjectors. The market for disposable autoinjectors involves the sales of devices designed to replace traditional pre-filled syringes, aiming to eliminate psychological barriers by concealing the needle from the patient's view. These autoinjectors integrate a spring-powered mechanism with a shielded needle for subcutaneous or intramuscular administration of the required drug solution. They find application in various therapies such as rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and others, administered through routes like subcutaneous and intramuscular. Distribution channels include online retailers and pharmacies, and they are utilized in diverse settings, including home care, hospitals, clinics, and others.

The autoinjectors market research report is one of a series of new reports that provides autoinjectors market statistics, including autoinjectors industry global market size, regional shares, competitors with an market share, detailed autoinjectors market segments, market trends and opportunities, and any further data you may need to thrive in the autoinjectors industry. This autoinjectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the autoinjectors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in autoinjectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the autoinjectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The autoinjectors market consists of sales of disposable and reusable autoinjectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.